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SUMMARY
 
Pregnancy-associated 
 
Plasmodium falciparum
 
 malaria
(PAM) is a major cause of morbidity and mortality in
African women and their offspring. PAM is characterized by
accumulation of infected erythrocytes (IEs) that adhere to
chondroitin sulphate A (CSA) in the placental intervillous
space. We show here that human monoclonal IgG antibodies
with speciﬁcity for variant surface antigens (VSA) speciﬁcally
expressed by CSA-adhering IEs (VSA
 
PAM
 
) can be used 
 
in
vitro
 
 to select parasites from nonpregnant donors to express
VSA
 
PAM
 
 and that this selection for VSA
 
PAM
 
 expression
results in preferential transcription of var2csa. The results
corroborate current efforts to develop PAM-speciﬁc vaccines
based on VAR2CSA.
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INTRODUCTION
 
Children living in areas of stable 
 
Plasmodium falciparum
 
transmission acquire substantial protective immunity
against malaria during the ﬁrst decade of life. Protection is
mediated to a large extent by variant surface antigen (VSA)-
speciﬁc IgG. Nevertheless, women in such areas remain
highly susceptible to 
 
P. falciparum
 
 infection if they become
pregnant, as the parasites can switch to expression of
particular VSA (called VSA
 
PAM
 
), which allow infected
erythrocyte (IE) sequestration in the placenta, but which are
not compatible with parasite survival in a nonpregnant
host. Acquired immunity to PAM is mediated by VSA
 
PAM
 
-
speciﬁc IgG that either opsonizes IEs for phagocytosis or
interferes with chondroitin sulphate A (CSA)-speciﬁc
adhesion of IEs (1). VAR2CSA, which is a member of
the 
 
P. falciparum
 
 erythrocyte membrane protein 1 (PfEMP1)
family of VSA, appears to be the dominant or only
pregnancy-associated 
 
Plasmodium falciparum
 
 malaria
(PAM) type VSA in the 
 
P. falciparum
 
 genome, and is
therefore the main target of current efforts to develop a
vaccine against PAM (2). To assist this work, we have
developed a panel of VSA
 
PAM
 
-speciﬁc human IgG1
monoclonal antibodies (3), which can opsonize VSA
 
PAM
 
-
expressing IEs for phagocytosis and interfere with IE
adhesion to CSA (Barfod 
 
et
 
 
 
al
 
. unpublished data). These
antibodies can be used to enrich for VSA
 
PAM
 
 expression in
parasites not expressing VSA
 
PAM
 
 but obtained from women
with PAM (3). In the present study we used two of the
above-mentioned monoclonal antibodies to select for
VSA
 
PAM
 
 expression in parasites from nonpregnant donors.
One antibody (PAM1·4) was chosen because it appears to
react with most or all parasites expressing VSA
 
PAM
 
. The
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other antibody (PAM8·1) was chosen because it reacts with
a well-deﬁned, but inter-clonally variant, epitope in the
DBL3X domain of VAR2CSA.
 
MATERIALS AND METHODS
 
Monoclonal antibodies
 
We used eight VSA
 
PAM
 
-speciﬁc monoclonal IgG1 antibodies
generated as described elsewhere (3; 4). VSA
 
PAM
 
 is deﬁned
here as IE surface-expressed VSA, which are signiﬁcantly
better recognized by plasma IgG from 
 
P. falciparum
 
-
exposed multigravidae than from sympatric men, and where
the recognition by plasma IgG from these men is not
signiﬁcantly different from recognition by plasma IgG from
nonexposed controls. In contrast, typical non-PAM VSAs
are better recognized by plasma IgG from 
 
P. falciparum
 
-
exposed adults than from nonexposed donors, without
marked sex-dependent differences. Seven of the monoclonal
antibodies used here are speciﬁc for inter-clonally variant
epitopes in either the DBL3-X or the DBL5-
 
ε
 
 domain of
VAR2CSA (3). The exact speciﬁcity of the last antibody
(PAM1·4) remains undeﬁned, but it appears to recognize a
conformational, and possibly discontinuous, epitope in
VAR2CSA that is difﬁcult to reproduce in recombinant
constructs (3). PAM1·4 recognizes VSA
 
PAM
 
 expressed by
most or all 
 
P. falciparum
 
 genotypes, whereas the VAR2CSA
DBL3-X epitope recognized by PAM8·1 is present in some,
but not all 
 
P. falciparum
 
 clones (3). Both PAM1·4 and PAM8·1
can opsonize VSA
 
PAM
 
-expressing IEs for phagocytosis
and interfere with their adhesion to CSA (Barfod 
 
et
 
 
 
al.
 
 in
preparation).
 
Malaria parasites
 
We used the two long-term 
 
in vitro
 
-adapted parasites 3D7
and HB3. The 3D7 clone was originally derived from NF54
parasites isolated from a Dutch girl near Amsterdam
airport (5). It was chosen here because it can be selected for
expression of VSA
 
PAM
 
 that react with PAM1·4 but not
PAM8·1 (3). HB3 was cloned from the Honduras I/CDC
parasite strain (6), and was chosen because it can be selected
for expression of VSA
 
PAM
 
 reactive with PAM1·4 and
PAM8·1. All parasites were grown in 0
 
+
 
 erythrocytes as
described (3).
 
Antibody selection for VSA
 
PAM
 
 expression
 
Selection for VSA
 
PAM
 
 expression was done essentially as
described elsewhere (7). In brief, monoclonal PAM1·4  or
PAM8·1 antibodies were immobilized on Protein A-coated
magnetic beads (Dynal) and mixed with 3D7- or HB3-IEs.
IEs adhering to the antibody-coated beads were isolated in
a strong magnetic ﬁeld and subsequently returned to 
 
in vitro
 
culture. Selection protocol was repeated when multiplication
of the antibody-selected parasites allowed it. VSA expression
was assessed by ﬂow cytometry analysis as described elsewhere
(8). We used plasma from 10 
 
P. falciparum
 
-exposed multi-
gravidae, 10 sympatric men, and 10 nonexposed controls to
assess the sex-speciﬁcity of VSA recognition. According to
the original criteria (9), sex-speciﬁc recognition requires that
(i) levels of IE-surface reactive IgG are signiﬁcantly higher
in 
 
P. falciparum
 
-exposed multigravidae than in sympatric
men, and that (ii) the difference in IgG levels in 
 
P. falciparum
 
-
exposed men and nonexposed controls is not statistically
signiﬁcant. We used term plasma from 30 
 
P. falciparum
 
-exposed
women (10 pregnant for the ﬁrst time, 10 for the third
time, and 10 for the ﬁfth time) to assess parity-dependency,
which requires a statistically signiﬁcant relationship between
IgG levels and number of pregnancies in 
 
P. falciparum
 
-
exposed women (9). Parasite isolates were only considered
to express VSA
 
PAM
 
 if plasma IgG recognition of IEs was
both sex-speciﬁc and parity-dependent.
 
Analysis of 
 
var
 
 gene transcription
 
Late-stage IEs were isolated by magnetic separation as
described (8) and returned to culture overnight to obtain
ring-stage IEs. Genomic DNA was isolated with a QIAamp
blood kit (Qiagen), and total RNA extracted (TRIzol,
Invitrogen) and treated with DNase I (Invitrogen) for 30 min
(10). The absence of DNA in RNA samples was conﬁrmed
as described (11). Reverse transcription was performed
using Superscript II (Invitrogen) and random hexamer
primers, followed by real-time PCR to quantify 
 
var
 
 transcript
abundances as described (11). We used primer pairs
speciﬁc for the 59 
 
var 
 
genes in the 3D7 genome (12) and for
45 
 
var
 
 genes in the HB3 genome (Table S1 in Supporting
Information). The latter were tested on genomic DNA
dilutions to ascertain appropriate fragment size, melting
temperature,  and ampliﬁcation efﬁciency compared to
the internal control 
 
seryl-tRNA synthetase
 
. All primer
pairs varied less than two Ct values from that of the internal
control and ampliﬁed single fragments of the expected
sizes.
 
Statistical analysis
 
Differences in antibody levels among plasma from 
 
P. falciparum
 
-
exposed multigravidae, 
 
P. falciparum
 
-exposed men, and
nonexposed control donors were analysed by one-way
 
anova
 
, or by one-way analysis of ranks for non-normal
distributed data. If statistically signiﬁcant (
 
P 
 
< 0·05)
overall differences were detected, signiﬁcant pair-wise 
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differences were isolated by Holm-Sidak’s or Dunn’s test for
normal- and non-normal-distributed data, respectively. Parity-
dependency was analysed by Pearson product moment
correlation.
 
RESULTS
 
Human monoclonal IgG can select 
 
Plasmodium 
falciparum
 
-IEs for expression of VSA
 
PAM
 
The VSA expressed on the surface of unselected 3D7- and
HB3-IEs were signiﬁcantly better recognized by plasma IgG
from 
 
P. falciparum
 
-exposed donors of both sexes than by
IgG from nonexposed donors, whereas levels in exposed
men and multigravidae were not signiﬁcantly different from
each other. Furthermore, IE surface-reactive IgG levels did
not depend on parity (Table 1 and Figure 1a). Thus, unselected
3D7 and HB3 both showed typical non-PAM-type plasma
antibody recognition patterns of IE surface-expressed VSA.
This was conﬁrmed by the nonreactivity of 3D7- and
HB3-IEs with all eight VSA
 
PAM
 
-speciﬁc monoclonal antibodies
(Figure  1d). When VSA expression was re-assessed after
three rounds of selection (about 6 weeks after the ﬁrst round
of selection), the recognition of 3D7- and HB3-IEs selected
on either PAM1·4 or PAM8·1 all showed an indeterminate
VSA phenotype, where one but not both criteria for
sex-speciﬁc antibody recognition were met (Table  1 and
Figure  1b). PAM8·1-selected 3D7 remained nonreactive
with the four monoclonal antibodies used for testing at this
time (PAM1·4, PAM3·10, PAM4·7, and PAM8·1), whereas
the other three parasite lines showed reactivity with at least
one of them (Figure 1e). These results suggested that further
rounds of selection might lead to deﬁnite VSA
 
PAM
 
 expres-
sion, at least for PAM1·4-selected 3D7, PAM1·4- and
PAM8·1-selected HB3. Indeed, PAM1·4-selected 3D7, as
well as PAM1·4- and PAM8·1-selected HB3 had all acquired
a typical sex-speciﬁc and parity dependent VSA
 
PAM
 
 expres-
sion pattern after four additional rounds of selection
(Table 1 and Figure 1c), and reacted with all the monoclonal
antibodies except the VAR2CSA DBL5-
 
ε
 
-speciﬁc PAM4·7
(Figure 1f). In contrast, 3D7 selected seven times for reactivity
with PAM8·1 retained an indeterminate sex-speciﬁcity
pattern also seen after three rounds of selection, did not
acquire the parity-dependent pattern typical of VSA
 
PAM
 
-
expressing lines (Table 1), and did not react with any of the
eight VSA
 
PAM
 
-speciﬁc monoclonal antibodies (Figure  1f).
Thus, PAM8·1 could not be used to select 3D7 for VSA
 
PAM
 
reactivity, consistent with the absence of the predicted
epitope for this antibody in the VAR2CSA DBL3-X domain
of this parasite (3).
 
Acquisition of VSA
 
PAM
 
 expression following 
antibody-selection is associated with selective 
transcription of 
 
var2csa
 
Transcripts of 
 
var2csa
 
 (PFL0030c) constituted 7% of total
measured 
 
var
 
 gene transcripts in unselected 3D7 parasites,
increasing to 80% after seven rounds of PAM1·4 selection.
In contrast, PAM8·1 selection did not affect the proportion
of 
 
var2csa
 
 transcripts in 3D7 (Figure 1g). The HB3 genome
contains two 
 
var2csa
 
 paralogs, 
 
var2csa-A
 
 and 
 
var2csa-B
 
(13). In unselected HB3 parasites, 
 
var2csa-A
 
 transcripts
constituted 1% of the measured 
 
var
 
 transcripts, increasing
to 28% and 4% after seven rounds of selection by PAM1·4
and PAM8·1, respectively (Figure 1h). Transcript levels
of the 
 
var2csa-B
 
 gene increased from 23% to 57% and
92% after seven rounds of selection by PAM1·4 and
PAM8·1, respectively (Figure 1h). No 
 
var
 
 transcript other than
Table 1 Changes in plasma antibody recognition pattern of infected erythrocytes following selection with VSAPAM-reactive human mono-
clonal antibodies
Parasite Antibodya
Rounds of selection for antibody recognition
03 7
Sex-speciﬁcityb Parity-dependency Sex-speciﬁcity Parity-dependency Sex-speciﬁcity Parity-dependency
3D7 PAM1·4 No No: P(r) = 0·87 Indeterminate n.d. Yes Yes: P(r) = 0·002
PAM8·1 Indeterminate n.d. Indeterminate No: P(r) = 0·41
HB3 PAM1·4 No No: P(r) = 0·55 Indeterminate n.d. Yes Yes: P(r) = 0·006
PAM8·1 Indeterminate n.d. Yes Yes: P(r) = 0·037
aHuman monoclonal VSAPAM-speciﬁc antibody used for selection.
bDetermination of sex-speciﬁcity involves a two-step procedure: ﬁrst establishment that IE surface-reactive IgG levels in at least one of the 
three donor categories (exposed multigravidae, exposed men, and unexposed controls) differs from at least one other category. Only if this is 
the case (as it was here: P < 0·001 in all cases), can sex-speciﬁcity be conﬁdently assessed by post hoc testing for signiﬁcant (P < 0·05) 
pair-wise differences. The result of this post hoc testing is indicated here as No: none of the two post hoc criteria for sex-speciﬁcity were met, 
Indeterminate: only one of the criteria was met. Yes: both criteria were met. See Materials and Methods for further details.344 © 2009 The Authors
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var2csa showed marked changes, and var2csa was therefore
the dominant transcript in all the parasites following
antibody selection. The dominance of var2csa-B transcripts
relative to var2csa-A in HB3 after PAM8·1 selection, suggested
that the DBL3-X domain in the protein encoded by var2csa-B
might be of the FCR3-type recognized by PAM8·1, whereas
the corresponding domain encoded by var2csa-A might be
of the 3D7-type (PFL0030 c) not recognized by PAM8·1 (2).
Figure 1 Changes in VSA expression and var gene transcription following selection for expression of VSAPAM reactive with human monoclonal antibodies.
Recognition of IEs by plasma IgG from 10 P. falciparum-exposed multigravidae (Exp. MG), 10 sympatric men (Ex. men) and 10 nonexposed 
controls (Unexp. ctrls) before selection (a), and after three (b) or seven (c) rounds of selection by human monoclonal IgG antibody PAM1·4. 
Results in panels A-C are presented as medians (horizontal line), central 50% of data points (boxes), central 80% of data points (whiskers) 
and outliers (•). In addition, statistically signiﬁcant (P < 0·05) pair-wise differences are indicated by heavy horizontal bars along the top of 
the panels. Recognition of IEs by human monoclonal VSAPAM-speciﬁc IgG antibodies before selection (d), and after three (e) or seven 
(f) rounds of selection. Results in panels D–F are presented as individual data points. Negative cut-off, deﬁned as the upper level of recognition 
of unselected parasites, is indicated as a dashed horizontal line. The proportion of var2csa transcripts among all var transcripts in 3D7 
(g) and HB3 (h) before selection and after seven rounds of selection. Panel (i) shows the amino acid sequence of the PAM8·1-speciﬁc region 
of VAR2CSA DBL3-X in the two VAR2CSA paralogs in HB3, FCR3, and 3D7 parasites. Amino acid differences between the two HB3 
sequences and the PAM8·1-reactive FCR3 sequence are underlined.© 2009 The Authors 345
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However,  var2csa-A and var2csa-B encode an identical
amino acid sequence in the region spanning the PAM8·1
epitope, and this sequence was of the FCR3-type (Figure 1i).
The var2csa-A : var2csa-B transcripts may therefore reﬂect a
founder effect.
DISCUSSION
The VSA subset VSAPAM is expressed by P. falciparum
involved in pregnancy-associated malaria (PAM). VSAPAM-
speciﬁc IgG mediates acquired immunological protection
against PAM, and the PfEMP1 variant VAR2CSA appears
to be the main or only target of these antibodies. VAR2CSA
is therefore the leading candidate for development of vaccines
against PAM.
We used monoclonal human IgG antibodies to select
erythrocytes infected by two genotypically distinct labora-
tory P. falciparum clones derived from nonpregnant donors
for expression of VSAPAM. Parasites acquiring expression of
VSAPAM following selection showed increased levels of
transcripts encoding the PfEMP1 variant VAR2CSA, which
appears to be the only PAM-type VSA in the P. falciparum
genome. The results obtained in the study are important for
several reasons.
First they support the hypothesis that all P. falciparum
parasites have the capacity to express VSAPAM. This hypothesis
is supported by previously published data that all P. falci-
parum genomes appear to contain at least one paralog of
the gene encoding the only known VSAPAM-type antigen,
VAR2CSA (11,14). Furthermore, this gene is selectively
transcribed by placental parasites (and following selection
for adhesion to CSA in vitro) and VAR2CSA is expressed on
the IE surface (15–17).
Second, they indicate that P. falciparum parasites regularly
and spontaneously switch to expression of VSAPAM in the
absence of an external signal, for example pregnancy-
associated hormonal changes. It has been speculated that
switching to VSAPAM expression requires signals from the
pregnant host, for example hormones, and that selection
therefore might not be possible unless the parasite is derived
from such a host. It has also been argued that selection of
parasites by panning on CSA in vitro might result in expres-
sion of antigens of dubious relevance to the antigens
expressed as a result of in vivo selection occurring in the
pregnant woman. Our data show that switching to expres-
sion of genuine VSAPAM can occur in vitro in the absence of
external signals, in line with other recent evidence (18). By
extension, these ﬁndings suggest that switching to VSAPAM
in vivo also occurs spontaneously regardless of the pregnancy
status of the host. In a pregnant host, such parasites will
often be at a selective advantage (because of the frequent
absence of VSAPAM-speciﬁc immunity in women of low
parity) (19), whereas they appear to be unable to survive in
a nonpregnant host (20).
Third, our results support the hypothesis that although
interclonal variation in VAR2CSA is the result of antibody-
driven positive selection, the diversity of functionally
important antibody epitopes in the molecule is constrained
(21). Thus, some parasites can express VAR2CSA without
being vulnerable to recognition by certain VAR2CSA-
reactive antibodies, because of variation in deﬁned parts of
VAR2CSA. The persistent nonrecognition by PAM8·1 of
VAR2CSA-expressing 3D7 is a case in point. At the same
time, the PAM8·1 antibody, originally identiﬁed by its
reactivity with VSAPAM-expressing FCR3-IEs (3), was
effectively selected for VSAPAM expression in the genetically
unrelated HB3 clone. The signiﬁcance of these ﬁndings is
underscored by the fact that PAM8·1 efﬁciently opsonizes
IEs for phagocytosis as well as interferes with IE adhesion
to CSA (Barfod et al. in preparation). Our study also corrob-
orates existing evidence that PAM1·4 recognizes most if not
all VSAPAM-expressing parasites by recognizing a functionally
highly constrained and conformation-dependent discontinuous
epitope in VAR2CSA (3). Like PAM8·1, PAM1·4 is an
opsonin and capable of interfering with IE adhesion to
CSA (Barfod et al. in preparation). Therefore, the PAM1·4
epitope is a highly attractive candidate for development
of a PAM-speciﬁc vaccine, and its characterization is a
matter of the highest priority in our current research.
Although the theoretical possibility of another, non-
PfEMP1 target of PAM1·4 remains, available evidence point
to VAR2CSA.
In conclusion, our evidence support current efforts to
develop PAM-speciﬁc vaccines based on VAR2CSA and
highlight the versatility of human monoclonal anti-
bodies generated from clinically immune donors in these
investigations.
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